GRAL
What one share of GRAIL holds
Services – Medical Laboratories
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
GRAIL’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.11 |
|---|---|
| Profit | −$9.75 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$7.37 |
| Cash and investments | $1.25 |
| Book value | $56.93 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $1.79 | −$173.89 | $0.74 | −$18.81 | — | — |
| 2023 | $3.00 | −$47.21 | $0.42 | −$19.60 | — | — |
| 2024 | $3.94 | −$63.54 | $0.16 | −$18.26 | — | $73.86 |
| 2025 | $4.00 | −$11.11 | $0.02 | −$8.16 | — | $63.92 |